Clinical Trial Update: Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial update of the combination therapy S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Colorectal, Cancer | Phase 2 | Status: COMPLETED